Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 2—February 2011
Letter

No Xenotropic Murine Leukemia Virus–related Virus Detected in Fibromyalgia Patients

Joanna Luczkowiak, Olalla Sierra, Jorge Juan González-Martín, Gabriel Herrero-Beaumont, and Rafael DelgadoComments to Author 
Author affiliations: Author affiliations: Hospital Universitario 12 de Octubre, Madrid, Spain (J. Luczkowiak, O. Sierra, R. Delgado); IIS-Fundación Jiménez Díaz, Madrid (J.J. González-Martín, G. Herrero-Beaumont)

Main Article

Figure

Testing for xenotropic murine leukemia virus–related virus (XMRV) in patients with fibromyalgia. Lanes 1 and 13, molecular weight marker ΦX174RF HaeIII; lanes 2–5, hBG for patients 1–4 (primers: hBG-FI-170/hBG-RI-273 (103 bp); lanes 6–12, positive control (pcDNA3.1-XMRV-Vp62) 1,000 copies (lanes 6 and 10) and 100 copies (lanes 7–9 and 11–12); lane 6, primers gag 419F/1154R (735 bp); lane 7, primers gag MLV-GAG-I-F/MLV-GAG-I-R (413 bp); lane 8, primers gag MLV-NP116/MLV-NP117 (380 bp); lane 9, pr

Figure. Testing for xenotropic murine leukemia virus–related virus (XMRV) in patients with fibromyalgia. Lanes 1 and 13, molecular weight marker ΦX174RF HaeIII; lanes 2–5, hBG for patients 1–4 (primers: hBG-FI-170/hBG-RI-273 (103 bp); lanes 6–12, positive control (pcDNA3.1-XMRV-Vp62) 1,000 copies (lanes 6 and 10) and 100 copies (lanes 7–9 and 11–12); lane 6, primers gag 419F/1154R (735 bp); lane 7, primers gag MLV-GAG-I-F/MLV-GAG-I-R (413 bp); lane 8, primers gag MLV-NP116/MLV-NP117 (380 bp); lane 9, primers gag XMRV-FI-441/XMRV-RI-566 (125 bp); lane 10, primers env 5922F/6273R (351 bp); lane 11, primers env 5922F/6173R (252 bp); lane 12, primers env 5942F/6159R (218 bp).

Main Article

Page created: July 13, 2011
Page updated: July 13, 2011
Page reviewed: July 13, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external